Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

2026-02-25 04:19:08

Liminatus Pharma, Inc. (NASDAQ: LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of a public offering expected to raise approximately $4.0 million in gross proceeds. The offering includes 13,813,000 shares (or pre-funded warrants) and warrants to purchase up to 20,719,500 shares, at a combined price of $0.29 per share. The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.